Clinical Trial

A Phase 1b/2 Trial Evaluating Safety and Efficacy of CAPecitabine in Combination With Ni-rapaRIb in HER2-negative Advanced Breast canCEr

Name: A Phase 1b/2 Trial Evaluating Safety and Efficacy of CAPecitabine in Combination With Ni-rapaRIb in HER2-negative Advanced Breast canCEr — clinical trial record (NCT05519670)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: CAPRICE

Not Yet Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

This study will be to combine oral capecitabine and oral niraparib such thz association may increase clinical benefits of PARP inhibitors in germline BRCA mutated HER2 negative advanced breast cancer patients.

Trial Details

NCT Number	NCT05519670
Lead Sponsor	Institut Paoli-Calmettes Collaborators: GlaxoSmithKline
Conditions	Breast Cancer
Enrollment	72 participants
Start Date	2023-03
Primary Completion	2027-09 (estimated)
Study Completion	2027-12 (estimated)
Updated on ClinicalTrials.gov	2022-08-29